Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer

BACKGROUND: FOLFIRINOX prolongs survival in patients with metastatic pancreatic cancer and may also benefit patients with locally advanced pancreatic cancer (LAPC). Furthermore, it may downstage a proportion of LAPC into (borderline) resectable disease, however data are lacking. This review assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rombouts, Steffi J., Walma, Marieke S., Vogel, Jantien A., van Rijssen, Lennart B., Wilmink, Johanna W., Mohammad, Nadia Haj, van Santvoort, Hjalmar C., Molenaar, I. Quintus, Besselink, Marc G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Gastrointestinal Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090009/
https://www.ncbi.nlm.nih.gov/pubmed/27370653
http://dx.doi.org/10.1245/s10434-016-5373-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090009/
https://www.ncbi.nlm.nih.gov/pubmed/27370653
http://dx.doi.org/10.1245/s10434-016-5373-2

Ejemplares similares